Clinical trials: Stage III Skin Cancer
Cancer-related Fatigue, Neutropenia, Malignant
PG2 Breast Cancer Evaluation in Adjuvant Medicine Study
Adjuvant chemotherapy usually is recommended after surgery for breast cancer patients who are at significant risk for disseminated disease. Chemotherapy has been demonstrated to reduce the risk of breast cancer recurrence.
- Trial name
- PG2 BEAM (NCT03314805)
- Testing
- Astragalus polysaccharides 500 mg, EC Chemotherapy
- Where
- 5 sites in Taiwan
- Volunteers
- 67 people
- Sponsor
- PhytoHealth Corporation
Malignant Melanoma
Study of gp75 Vaccine in Patients With Stage III and IV Melanoma
Up to 24 patients with stage III or stage IV melanoma will be enrolled. Patients who are currently disease-free but at high risk for relapse are also eligible. Patients will receive vaccinations of gp75 at assigned dose levels.
- Trial name
- NCT00034554
- Testing
- gp75 DNA vaccine
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Eli Lilly and Company
Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)
This Phase III, randomized, double-blind, placebo-controlled, multicenter study will evaluate the efficacy and safety of giredestrant combined with palbociclib compared with letrozole combined with palbociclib in patients with…
- Trial name
- NCT04546009
- Testing
- Giredestrant, Letrozole, Palbociclib
- Where
- 255 sites in United States, Argentina and 28 more
- Volunteers
- 992 people
- Sponsor
- Hoffmann-La Roche
Melanoma
A Single Arm Study of Ipilimumab Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma
The purpose of this clinical research study is to evaluate the Best Overall Response Rate (BORR), (as per modified WHO criteria) in patients with previously treated melanoma-Stage III (unresectable) or Stage IV melanoma receiving…
- Trial name
- NCT00289627
- Testing
- ipilimumab (MDX-010, BMS-734016)
- Where
- 53 sites in United States, Austria and 8 more
- Volunteers
- 155 people
- Sponsor
- Bristol-Myers Squibb
Unresectable Stage III or Stage IV Melanoma
A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma
This is a study to determine the clinical benefit (how well the drug works), safety and tolerability of combining a) varlilumab and ipilimumab and b) varlilumab, ipilimumab, CDX-1401 and poly-ICLC.
- Trial name
- NCT02413827
- Testing
- Combination of varlilumab and ipilimumab, Cohort A: varlilumab & ipilimumab; Cohort B: varlilumab, ipilimumab, CDX-1401 & poly-ICLC
- Where
- 8 sites in United States
- Volunteers
- 9 people
- Sponsor
- Celldex Therapeutics
Breast Cancer
Gut and Tumor Microbiome in Patients With Early Stage (II-III), Locally Advanced or Advanced ER-positive and HER2-negative Breast Cancer.
The purpose of this research study is to collect samples of blood and stool and analyse primary tumor from participants with breast cancer to see how the bacteria in the body affect cancer and how well it responds to treatment.
- Trial name
- NCT06126003
- Testing
- Observation
- Where
- 6 sites in United States
- Volunteers
- 2 people
- Sponsor
- BioCorteX Inc
Melanoma (Skin)
Vaccine Therapy in Treating Patients With Malignant Melanoma
RATIONALE: Vaccines made from tumor cells may help the body build an effective immune response to kill tumor cells. PURPOSE: This phase II trial is studying vaccine therapy to see how well it works in treating patients with…
- Trial name
- NCT00128583
- Testing
- polyvalent melanoma vaccine
- Where
- 11 sites in United States, Australia
- Sponsor
- CancerVax Corporation
Breast Cancer, Breast Neoplasms
A Phase III Trial For Patients With Metastatic Breast Cancer
This is a phase III randomized study between the docetaxel/gemcitabine and docetaxel/ capecitabine doublets, with crossover to the alternate agent.
- Conditions
- Breast Cancer, Breast Neoplasms, Cancer of the Breast
- Trial name
- NCT00191152
- Testing
- gemcitabine, docetaxel, capecitabine
- Where
- 65 sites in United States, Argentina and 6 more
- Volunteers
- 475 people
- Sponsor
- Eli Lilly and Company
Advanced, Metastatic Breast Cancer
A Study to Investigate the Efficacy and Safety of Letrozole SIE Compared With Femara® (Both Combined With the CDK4/6 Inhibitor Ribociclib) in Postmenopausal Women With HR-Positive, HER2-Negative, Inoperable Locally Advanced or Metastatic Breast Cancer
The purpose of this study is to evaluate the efficacy and safety of Letrozole SIE (injectable) compared to Femara® (oral tablet), both given together with ribociclib, for the first-line treatment of postmenopausal women with…
- Trial name
- SIE-3 (NCT07340658)
- Volunteers
- 300 people
- Sponsor
- Rovi Pharmaceuticals Laboratories
Melanoma
Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.
The purpose of the Columbus-AD study is to evaluate the efficacy and safety of 12 months of encorafenib in combination with binimetinib in adjuvant setting of BRAF V600E/K mutant stage IIB/C melanoma versus the current standard…
- Trial name
- COLUMBUS-AD (NCT05270044)
- Testing
- Encorafenib and Binimetinib
- Where
- 155 sites in Argentina, Australia and 21 more
- Volunteers
- 815 people
- Sponsor
- Pierre Fabre Medicament
Stage IIIB Skin Melanoma, Stage IIIC Skin Melanoma
A Study of Transgenic Lymphocyte Immunization (TLI) Against Telomerase in Subjects With Stage III Melanoma
The purpose of this study is to assess the safety, efficacy, and immunological response to the study product, TLI, as an adjuvant therapy in subjects with Stage III Melanoma. Normal cells in the body have an established lifespan.
- Trial name
- NCT00925314
- Testing
- CB-10-01 (Transgenic Lymphocyte Immunization)
- Where
- 5 sites in United States
- Volunteers
- 20 people
- Sponsor
- Cosmo Bioscience
Melanoma, Melanoma (Skin)
A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma
The aim of study is to investigate the efficacy, safety, immunogenicity, pharmacokinetics, and pharmacodynamics of BCD-217 followed by prolgolimab monotherapy versus prolgolimab monotherapy as first-line therapy in subjects with…
- Conditions
- Melanoma, Melanoma (Skin), Melanoma Stage III, Melanoma Stage IV
- Trial name
- OCTAVA (NCT05732805)
- Testing
- BCD-217, BCD-100
- Where
- 63 sites in Belarus, India and 1 more
- Volunteers
- 270 people
- Sponsor
- Biocad
Advanced, Metastatic Breast Cancer
Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer
The primary purpose of this study was to assess the efficacy of ribociclib, as measured by progression free survival (PFS), in postmenopausal women with hormone receptor positive (HR+), human epidermal growth factor receptor 2…
- Trial name
- MONALEESA-2 (NCT01958021)
- Testing
- Ribociclib, Letrozole
- Where
- 221 sites in United States, Argentina and 27 more
- Volunteers
- 668 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
TAC Versus TC for Adjuvant Breast Cancer
The purpose of this research study is to find out what effects (good and bad) TC or TAC has on early stage HER2- breast cancer.
- Trial name
- NCT00493870
- Testing
- Docetaxel, Doxorubicin, Cyclophosphamide
- Where
- 95 sites in United States
- Volunteers
- 1,961 people
- Sponsor
- US Oncology Research
Neoplasms, Breast
A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer
A study to compare the safety and efficacy of an aromatase inhibitor in combination with lapatinib, trastuzumab or both for the treatment of hormone receptor positive, HER2+ metastatic breast cancer (MBC).
- Trial name
- NCT01160211
- Testing
- Lapatinib, Trastuzumab, Aromatase Inhibitor
- Where
- 110 sites in United States, Argentina and 27 more
- Volunteers
- 369 people
- Sponsor
- Novartis Pharmaceuticals
Stage IV Melanoma, Stage III Melanoma
Chemotherapy With or Without Immunotherapy in Treating Patients With Stage III or Stage IV Melanoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Injecting allovectin-7 into a person's melanoma cells may make the body build an immune response that will…
- Conditions
- Stage IV Melanoma, Stage III Melanoma, Recurrent Melanoma
- Trial name
- NCT00003647
- Testing
- allovectin-7, allovectin-7/dacarbazine, dacarbazine
- Where
- 44 sites in United States
- Sponsor
- Vical
Breast Cancer
Vaccine Therapy in Treating Women With Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Vaccines may make the body build an immune response to kill tumor cells.
- Trial name
- NCT00003638
- Testing
- Detox-B adjuvant, THERATOPE STn-KLH vaccine, keyhole limpet hemocyanin
- Where
- Canada
- Volunteers
- 950 people
- Sponsor
- Oncothyreon Canada Inc.
Triple-Negative Breast Cancer (TNBC)
Fasten Onco Digital Therapy During Neoadjuvant Treatment for Triple-Negative Breast Cancer
This randomized, multicenter, open-label clinical study will evaluate whether adding the Fasten Onco digital therapy, which supports a fasting-mimicking diet (FMD), to standard neoadjuvant treatment can reduce treatment-related…
- Trial name
- FAST-01 (NCT07884721)
- Testing
- Fasten Onco, Standard Neoadjuvant Treatment
- Where
- 7 sites in France
- Volunteers
- 144 people
- Sponsor
- FASTEN
ER-Positive HER2-Negative Breast Cancer
A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease
The study is intended to show superiority of AZD9833 in combination with palbociclib (a CDK4/6 inhibitor) versus anastrozole (an aromatase inhibitor) and palbociclib as the initial treatment of patients with hormone…
- Trial name
- SERENA-4 (NCT04711252)
- Testing
- AZD9833, Anastrozole, Palbociclib
- Where
- 263 sites in United States, Austria and 25 more
- Volunteers
- 1,371 people
- Sponsor
- AstraZeneca
Breast Cancer Female, Stage II Breast Cancer
Predicting BReast cAncer Response to neoadjuVant Therapy by ctDNA Assessment
This is a prospective and observational study, aiming to determine the detection rate and change of CtDNA in blood samples of cancer patients before, during and after neoadjuvant treatment.
- Conditions
- Breast Cancer Female, Stage II Breast Cancer, Stage III Breast Cancer, HER2-positive Breast Cancer
- Trial name
- BRAVA (NCT06087120)
- Where
- 3 sites in Indonesia, Vietnam
- Volunteers
- 125 people
- Sponsor
- Gene Solutions